Comparison of Deep Neuromuscular Block and Moderate Neuromuscular Block on Quality of Recovery in Patients Undergoing Robotic Gastrectomy

December 15, 2017 updated by: Yonsei University
The purpose of this study is to investigate and compare the postoperative quality of recovery between the deep neuromuscular blockade and moderate neuromuscular blockade during robotic gastrectomy.

Study Overview

Study Type

Interventional

Enrollment (Actual)

56

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Seoul, Korea, Republic of, 120-752
        • Department of Anesthesiology and Pain Medicine Anesthesia and Pain Research Institute Yonsei University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • adult patients aged 19-80 years who are scheduled for robotic gastrectomy

Exclusion Criteria:

  • Neuromuscular disease
  • History of malignant hyperthermia
  • Significant renal or hepatic dysfunction
  • Allergy to sugammadex or rocuronium

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Deep neuromuscular blockade
Rocuronium will be administered continuously to achieve post-tetanic count 1-2 during surgery.
neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
Active Comparator: Moderate neuromuscular blockade
Rocuronium will be administered continuously to achieve Train-of-four 1-2 during surgery.
neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative quality of recovery
Time Frame: within 48 hours after the end of surgery.
The postoperative quality of recovery will be evaluated at 24 and 48 hours after the end of surgery by the investigator who are blinded to the group assignments.
within 48 hours after the end of surgery.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Surgical condition
Time Frame: within 48 hours after the end of surgery
Surgical condition will be evaluated after the end of surgery by the investigator who are blinded to the group assignments.
within 48 hours after the end of surgery
shoulder pain
Time Frame: within 48 hours after the end of surgery
shoulder pain will be evaluated after the end of surgery by the investigator who are blinded to the group assignments.
within 48 hours after the end of surgery
abdominal pain
Time Frame: within 48 hours after the end of surgery
abdominal pain will be evaluated after the end of surgery by the investigator who are blinded to the group assignments.
within 48 hours after the end of surgery
nausea and vomiting
Time Frame: within 48 hours after the end of surgery
nausea and vomiting will be evaluated after the end of surgery by the investigator who are blinded to the group assignments.
within 48 hours after the end of surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 6, 2016

Primary Completion (Actual)

February 27, 2017

Study Completion (Actual)

February 27, 2017

Study Registration Dates

First Submitted

May 4, 2016

First Submitted That Met QC Criteria

May 4, 2016

First Posted (Estimate)

May 5, 2016

Study Record Updates

Last Update Posted (Actual)

December 18, 2017

Last Update Submitted That Met QC Criteria

December 15, 2017

Last Verified

December 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

no plan to share data

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on General Anesthesia

Clinical Trials on Deep neuromuscular blockade

Subscribe